Home › Chronic Myelomonocytic Leukemia › California
Chronic Myelomonocytic Leukemia clinical trials in California
12 studies for Chronic Myelomonocytic Leukemia are looking for participants at sites in California.
Cities in California
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- City of Hope Comprehensive Cancer Center, Duarte
- UCLA Medical Center, Los Angeles
- Stanford Cancer Institute, Stanford
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT04996875TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
- Stanford University, Palo Alto
RecruitingPhase 1
Ages 18 to 80 · All sexes · Updated Aug 17, 2026 · NCT07302776Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
- Kaiser Permanente San Diego, San Diego
- Allergy & Asthma Clinical Research of the Bay Area, Walnut Creek
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT07143669Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
- City of Hope Medical Center, Duarte
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Jun 29, 2026 · NCT06815003A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Keck School of Medicine of USC, Los Angeles
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- City of Hope, Duarte
- Stanford, Palo Alto
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- City of Hope, Duarte
- Stanford Medical Center, Palo Alto
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Mar 16, 2026 · NCT06994676Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 5, 2026 · NCT06543381A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- Stanford University, Stanford
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 9, 2026 · NCT06950034Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- University of California Davis Health (UC Davis Health), Sacramento
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jan 5, 2026 · NCT05184842Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- University of California Irvine, Irvine
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Stanford Cancer Center, Palo Alto
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 26, 2025 · NCT03850574Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 15, 2025 · NCT06462365From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.